|Awarded On||August 19, 2020|
|Title||Targeting B Cells to Enhance Responses to Immune Checkpoint Blockade|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jennifer Wargo|
|Cancer Sites||Kidney and Renal Pelvis, Lung and Bronchus, Melanoma|
*Pending contract negotiation
We have made major advances in cancer treatment through the use of immunotherapy, which stimulates the body's immune system to fight tumors. This includes the use of immune checkpoint blockade, which works by taking the brakes off cancer-killing white blood cells known as T-cells. However not all patients benefit from this type of therapy, and critical research is needed to identify new ways to improve responses. Much of the research to date has focused on T-cells themselves, however these cells likely work in concert with other cells to help fight cancer. We recently studied how different immune cells influence responses to immunotherapy, and found that B-cells - which produce antibodies a...